Cargando…
Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy
BACKGROUND AND PURPOSE: Data regarding the effects of cannabidiol (CBD) on the quality of life (QOL) are currently inadequate. We assessed the QOL of pediatric patients with epilepsy who were treated with CBD. METHODS: This prospective, open-label study included pediatric and adolescent patients (ag...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neurological Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444566/ https://www.ncbi.nlm.nih.gov/pubmed/36062772 http://dx.doi.org/10.3988/jcn.2022.18.5.547 |
_version_ | 1784783255394844672 |
---|---|
author | Kim, Se Hee Choi, Han Som Koo, Chung Mo Joo, Bong-Rim Park, Byung-Joo Lee, Hae Kook Lee, Joon Soo Kim, Heung Dong Kang, Hoon-Chul |
author_facet | Kim, Se Hee Choi, Han Som Koo, Chung Mo Joo, Bong-Rim Park, Byung-Joo Lee, Hae Kook Lee, Joon Soo Kim, Heung Dong Kang, Hoon-Chul |
author_sort | Kim, Se Hee |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Data regarding the effects of cannabidiol (CBD) on the quality of life (QOL) are currently inadequate. We assessed the QOL of pediatric patients with epilepsy who were treated with CBD. METHODS: This prospective, open-label study included pediatric and adolescent patients (aged 2–18 years) with Dravet syndrome or Lennox-Gastaut syndrome. Oral CBD was administered at 10 mg/kg/day. The Korean version of the Quality Of Life in Childhood Epilepsy (QOLCE) questionnaire was administered when CBD treatment began and again after 6 months. Adaptive behavior was measured using the Korean versions of the Child Behavior Checklist (K-CBCL) and the second edition of the Vineland Adaptive Behavior Scales (Vineland-II). RESULTS: This study included 41 patients (11 with Dravet syndrome and 30 with Lennox-Gastaut syndrome), of which 25 were male. The median age was 4.1 years. After 6 months, 26.8% (11/41) of patients experienced a ≥50% reduction in the number of seizures. The total score for the QOLCE questionnaire did not change from baseline to after 6 months of CBD treatment (85.71±39.65 vs. 83.12±48.01, respectively; p=0.630). The score in the motor skills domain of Vineland-II reduced from 48.67±13.43 at baseline to 45.18±14.08 after 6 months of treatment (p=0.005). No other Vineland-II scores and no K-CBCL scores had changed after 6 months of CBD treatment. CONCLUSIONS: CBD is an efficacious antiseizure drug used to treat Dravet syndrome and Lennox-Gastaut syndrome. However, it did not improve the patient QOL in our study, possibly because all of our patients had profound intellectual disabilities. |
format | Online Article Text |
id | pubmed-9444566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean Neurological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-94445662022-09-13 Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy Kim, Se Hee Choi, Han Som Koo, Chung Mo Joo, Bong-Rim Park, Byung-Joo Lee, Hae Kook Lee, Joon Soo Kim, Heung Dong Kang, Hoon-Chul J Clin Neurol Original Article BACKGROUND AND PURPOSE: Data regarding the effects of cannabidiol (CBD) on the quality of life (QOL) are currently inadequate. We assessed the QOL of pediatric patients with epilepsy who were treated with CBD. METHODS: This prospective, open-label study included pediatric and adolescent patients (aged 2–18 years) with Dravet syndrome or Lennox-Gastaut syndrome. Oral CBD was administered at 10 mg/kg/day. The Korean version of the Quality Of Life in Childhood Epilepsy (QOLCE) questionnaire was administered when CBD treatment began and again after 6 months. Adaptive behavior was measured using the Korean versions of the Child Behavior Checklist (K-CBCL) and the second edition of the Vineland Adaptive Behavior Scales (Vineland-II). RESULTS: This study included 41 patients (11 with Dravet syndrome and 30 with Lennox-Gastaut syndrome), of which 25 were male. The median age was 4.1 years. After 6 months, 26.8% (11/41) of patients experienced a ≥50% reduction in the number of seizures. The total score for the QOLCE questionnaire did not change from baseline to after 6 months of CBD treatment (85.71±39.65 vs. 83.12±48.01, respectively; p=0.630). The score in the motor skills domain of Vineland-II reduced from 48.67±13.43 at baseline to 45.18±14.08 after 6 months of treatment (p=0.005). No other Vineland-II scores and no K-CBCL scores had changed after 6 months of CBD treatment. CONCLUSIONS: CBD is an efficacious antiseizure drug used to treat Dravet syndrome and Lennox-Gastaut syndrome. However, it did not improve the patient QOL in our study, possibly because all of our patients had profound intellectual disabilities. Korean Neurological Association 2022-09 2022-05-20 /pmc/articles/PMC9444566/ /pubmed/36062772 http://dx.doi.org/10.3988/jcn.2022.18.5.547 Text en Copyright © 2022 Korean Neurological Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Se Hee Choi, Han Som Koo, Chung Mo Joo, Bong-Rim Park, Byung-Joo Lee, Hae Kook Lee, Joon Soo Kim, Heung Dong Kang, Hoon-Chul Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy |
title | Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy |
title_full | Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy |
title_fullStr | Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy |
title_full_unstemmed | Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy |
title_short | Effects of Cannabidiol on Adaptive Behavior and Quality of Life in Pediatric Patients With Treatment-Resistant Epilepsy |
title_sort | effects of cannabidiol on adaptive behavior and quality of life in pediatric patients with treatment-resistant epilepsy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444566/ https://www.ncbi.nlm.nih.gov/pubmed/36062772 http://dx.doi.org/10.3988/jcn.2022.18.5.547 |
work_keys_str_mv | AT kimsehee effectsofcannabidiolonadaptivebehaviorandqualityoflifeinpediatricpatientswithtreatmentresistantepilepsy AT choihansom effectsofcannabidiolonadaptivebehaviorandqualityoflifeinpediatricpatientswithtreatmentresistantepilepsy AT koochungmo effectsofcannabidiolonadaptivebehaviorandqualityoflifeinpediatricpatientswithtreatmentresistantepilepsy AT joobongrim effectsofcannabidiolonadaptivebehaviorandqualityoflifeinpediatricpatientswithtreatmentresistantepilepsy AT parkbyungjoo effectsofcannabidiolonadaptivebehaviorandqualityoflifeinpediatricpatientswithtreatmentresistantepilepsy AT leehaekook effectsofcannabidiolonadaptivebehaviorandqualityoflifeinpediatricpatientswithtreatmentresistantepilepsy AT leejoonsoo effectsofcannabidiolonadaptivebehaviorandqualityoflifeinpediatricpatientswithtreatmentresistantepilepsy AT kimheungdong effectsofcannabidiolonadaptivebehaviorandqualityoflifeinpediatricpatientswithtreatmentresistantepilepsy AT kanghoonchul effectsofcannabidiolonadaptivebehaviorandqualityoflifeinpediatricpatientswithtreatmentresistantepilepsy |